Human Yellow Fever IgM (YF IgM) ELISA Kit (DEIA-Z5092)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma, biological fluids
Species Reactivity
Human
Intended Use
Human Anti-Yellow fever virus Env IgM (YFV Env-IgM) tests is an indirect ELISA suitable for detecting YFV-Env IgM in Human serum or plasma. Other biological fluids, including tissue culture medium, may be validated for user in vitro research use only (RUO), not for therapeutic or diagnostic use.
Storage
The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label. Stabilities of the working solutions are indicated under Reagent Preparation.
To Be Reconstituted: Store as indicated.
Sensitivity
The YFV-Env antigen coating level, HRP conjugate concentration, and sample Diluent are optimized to differentiate anti-YFV-Env IgG from background (non-antibody) signal with Human serum samples at an appropriate dilution. The positive controls at 100 U/ml represent ~ 100 ng/ml Human IgG. The lowest limit of detection is about 0.3 ng of Human IgG.
General Description
Yellow fever is a viral hemorrhagic disease spread between humans, as well as between certain other primates and humans, by the bite of yellow fever-infected mosquitoes. it is spread primarily by mosquitoes of the Aedes aegypti species. The virus is called simply Yellow fever virus (YFV) and belongs to the virus family Flaviviridae. Humans are a dead-end host, terminating the virus's life cycle and consequently suffering from much harsh symptoms than its native host. Yellow fever is a serious, potentially deadly flu-like disease spread by mosquitoes. This disease is most prevalent in tropical and subtropical areas. Yellow fever can't be passed directly from person to person through close contact. According to the recent analysis, there are an estimated 84 000-170 000 cases and up to 60 000 deaths due to yellow fever per year.
Yellow Fever Virus (YFV) is a positive- sense, ssRNA, (11 kb) encoding three structural (C, prM, E) and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). Env/E protein is the major inducer and target of virus neutralizing antibodies. The function of the virus E proteins is to attach the virus to receptors on host cells; they initiate the biggest immune response from the host. The M proteins appear to keep the E proteins functional during the assembly of new viruses. C proteins are found in the virus nucleocapsid.
YFV vaccine (killed virus) has been very effective and successful. Chimeric variants of YFV, that express E and prM proteins, are being used to produce vaccines against other arbovirus diseases such as dengue fever (DENV), West Nile (WNV), and Japanese encephalitis (JEV).

YFV Vaccines & Sample Testing
YFV vaccine came into use in 1938. It is on the WHO's List of Essential Medicines. YF-VAX®, Yellow Fever Vaccine, for subcutaneous use, is prepared by culturing the 17D-204 8 strain of yellow fever virus in chicken embryos. YFV vaccination provides life-long immunity and it has>90% efficacy. It has been administered to more than 600 million people worldwide. YF-17D is a live-attenuated vaccine that infects and replicates in target cells, vaccines who receive the YF-17D vaccine usually develop detectable viremia after vaccination. Therefore, antibodies to several structural (Env, prM, capsid) and non-structural proteins NS1-5 may be produced. Antibodies to NS1 are also found in natural infection.
YFV-17D, chimeric variants of YFV are being used to produce vaccines against other arbovirus diseases such as dengue fever (DENV), West Nile (WNV), and Japanese encephalitis (JEV). A new technology, called ChimeriVax has been developed to excise the specific genes that encode the E and prM proteins of the YFV and replace it with the gene for the E and prM protein of the target virus such as DENV. Recombinant RFV-17D chimeic vaccines may retain the NS1 protein so antibodies to NS1 will also be produced.
Serologically, an ELISA during the acute phase of the disease using specific IgM against yellow fever or an increase in specific IgG-titer (compared to an earlier sample) can confirm yellow fever. Together with clinical symptoms, the detection of IgM or a fourfold increase in IgG-titer is considered sufficient indication for yellow fever. Since these tests can cross-react with other flaviviruses, like dengue virus, these indirect methods cannot conclusively prove yellow fever infection. In a differential diagnosis, infections with yellow fever must be distinguished from other feverish illnesses like malaria. Other viral hemorrhagic fevers, such as Ebola virus, Lassa virus, Marburg virus, and Junin virus, must be excluded as cause.
Reconstitution And Storage
Wash Solution Concentrate (50x), 10ml: Dilute the entire volume 10ml + 490 ml with distilled or deionized water into a clean stock bottle. Label as 1X Wash Solution and store at 4°C for long term and ambient temp. for short term.
Sample/HRP Diluent Concentrate (20x), 10ml: Dilute the entire volume, 10ml + 190ml with distilled or deionized water into a clean stock bottle. Label as Working Sample Diluent (WSD) and store at 2-8°C until the kit lot expires or is used up.
Anti-Human IgM- HRP Conjugate Concentrate (100x), 0.11ml: in buffer with detergents and antimicrobial as stabilizers. Dilute fresh as needed; 10ul of concentrate to 1ml of Working Sample Diluent is sufficient for 1 8- well strip. Use within the working day and discard. Return 100X to 2-8°C storage.

Citations


Have you cited DEIA-Z5092 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections

ANTIVIRAL RESEARCH

Authors: Furuta, Yousuke; Takahashi, Kazumi; Shiraki, Kimiyasu; Sakamoto, Kenichi; Smee, Donald F.; Barnard, Dale L.; Gowen, Brian B.; Julander, Justin G.; Morrey, John D.

A series of pyrazinecarboxamide derivatives T-705 (favipiravir), T-1105 and T-1106 were discovered to be candidate antiviral drugs. These compounds have demonstrated good activity in treating viral infections in laboratory animals caused by various RNA viruses, including influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV). Treatment has in some cases been effective when initiated up to 5-7 days after virus infection, when the animals already showed signs of illness. Studies on the mechanism of action of T-705 have shown that this compound is converted to the ribofuranosyltriphosphate derivative by host enzymes, and this metabolite selectively inhibits the influenza viral RNA-dependent RNA polymerase without cytotoxicity to mammalian cells. Interestingly, these compounds do not inhibit host DNA and RNA synthesis and inosine 5'-mono phosphate dehydrogenase (IMPDH) activity. From in vivo studies using several animal models, the pyrazinecarboxamide derivatives were found to be effective in protecting animals from death, reducing viral burden, and limiting disease manifestations, even when treatment was initiated after virus inoculation. Importantly, T-705 imparts its beneficial antiviral effects without significant toxicity to the host. Prompt development of these compounds is expected to provide effective countermeasures against pandemic influenza virus and several bioweapon threats, all of which are of great global public health concern given the current paucity of highly effective broad-spectrum drugs. (C) 2009 Elsevier B.V. All rights reserved.

17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients

JOURNAL OF INFECTION

Authors: Wieten, R. W.; Goorhuis, A.; Jonker, E. F. F.; de Bree, G. J.; de Visser, A. W.; van Genderen, P. J. J.; Remmerswaal, E. B. M.; ten Berge, I. J. M.; Visser, L. G.; Grobusch, M. P.; van Leeuwen, E. M. M.

Background: The 17D live attenuated yellow fever (YF) vaccine is contra-indicated in immune-compromised individuals and may elicit a suboptimal immunologic response. The aim of this study is to assess whether long-term immune responses against the YF vaccine are impaired in immune-compromised patients. Materials and methods: Fifteen patients using different immunosuppressive drugs and 30 healthy individuals vaccinated 0-22 years ago were included. The serological response was measured using the plaque reduction neutralization test (PRNT). CD8(+) and CD4(+) T-cell responses were measured following proliferation and re-stimulation with YFV peptide pools. Phenotypic characteristics and cytokine responses of CD8(+) T-cells were determined using class I tetramers. Results: The geometric mean titre of neutralizing antibodies was not different between the groups (p = 0.77). The presence of YFV-specific CD4(+) and CD8(+) T-cell did not differ between patients and healthy individuals (15/15, 100.0% vs. 29/30, 96.7%, p = 0.475). Time since vaccination correlated negatively with the number of YFV-specific CD8(+) T-cells (r = -0.66, p = 0.0045). Percentages of early-differentiated memory cells increased (r = 0.67, p = 0.017) over time. Conclusion: These results imply that YF vaccination is effective despite certain immunosuppressive drug regimens. An early-differentiated memory-like phenotype persisted, which is associated with effective expansion upon re-encounter with antigen, suggesting a potent memory T-cell pool remains. (C) 2016 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket